Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of HTX-019 in healthy volunteers

Next Previous
X
Search
Trial Profile

Study of HTX-019 in healthy volunteers

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aprepitant (Primary) ; Fosaprepitant
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Pharmacokinetics; Registrational
  • Sponsors Heron Therapeutics

    • Most Recent Events

    • 09 Nov 2017 According to a Heron Therapeutics media release, the US FDA has approved CINVANTI (aprepitant) injectable emulsion, for intravenous infusion for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin and nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
    • 12 Jan 2017 According to a Heron Therapeutics media release, the company has submitted a New Drug Application (NDA) for HTX-019 (CINVANTI) for the prevention of chemotherapy induced nausea and vomiting. The filing includes data from this trial.
    • 23 Feb 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top